Search

The regeneration performance of an aged styrene–butadiene–styrene block copolymer (SBS) will be significantly influenced by different rejuvenators. The objective of this study was to comparatively investigate the regeneration effect of different SBS-modified asphalt regenerators on aged SBS-modified asphalt. Four types of different regenerant formulations were selected. The optimal rejuvenator content was determined firstly using conventional performance tests. The rheological properties of the aged SBS-modified asphalt binder were evaluated by multiple stress creep recovery (MSCR) experiments. Subsequently, the regeneration mechanism of the SBS-modified asphalt binder was investigated using thin-layer chromatography–flame ionization detection (TLC-FID) and Fourier transform infrared spectroscopy (FTIR). The results showed that the rejuvenator had a certain recovery effect on the penetration, softening point, and ductility of the SBS-modified asphalt binder after aging. The SBS-modified rejuvenating agent was the most favorable among the four types of rejuvenators, where a rejuvenator dosage of 12% showed the optimal rejuvenation effect. The addition of regenerators could appropriately improve the elastic deformation capacity of the aged asphalt binder. The epoxy soybean oil in the regenerant reacted with the aging SBS-modified asphalt binder, supplementing the lost oil in the aged SBS-modified asphalt binder, dispersing the excessive accumulation of asphaltene, and making the residual SBS swell again. The viscoelastic properties of the aging asphalt binder were improved by adjusting the content of components and functional groups to achieve the purpose of regeneration. [ABSTRACT FROM AUTHOR]

Cytosolic thiouridylase 2 (CTU2) is an enzyme modifying transfer RNAs post-transcriptionally, which has been implicated in breast cancer and melanoma development. And we found CTU2 participated in hepatocellular carcinoma (HCC) progression here. HepG2 cells as well as xenograft nude mice model were employed to investigate the role of CTU2 in HCC development in vitro and in vivo respectively. Further, we defined CTU2 as a Liver X receptor (LXR) targeted gene, with a typical LXR element in the CTU2 promoter. CTU2 expression was activated by LXR agonist and depressed by LXR knockout. Interestingly, we also found CTU2 took part in lipogenesis by directly enhancing the synthesis of lipogenic proteins, which provided a novel mechanism for LXR regulating lipid synthesis. Meanwhile, lipogenesis was active during cell proliferation, particularly in tumor cells. Reduction of CTU2 expression was related to reduced tumor burden and synergized anti-tumor effect of LXR ligands by inducing tumor cell apoptosis and inhibiting cell proliferation. Taken together, our study identified CTU2 as an LXR target gene. Inhibition of CTU2 expression could enhance the anti-tumor effect of LXR ligand in HCC, identifying CTU2 as a promising target for HCC treatment and providing a novel strategy for the application of LXR agonists in anti-tumor effect. 1.) CTU2 enhances proliferation of hepatoma carcinoma cells. 2.) CTU2 is the target gene of LXR, and LXR can transcriptionally activate CTU2 expression. 3.) CTU2 can promote protein synthesis of lipogenic genes. 4.) Inhibiting CTU2 expression can synergistically enhance the inhibitory effects of LXR ligands on HCC growth. [ABSTRACT FROM AUTHOR]